Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

NBI-1117567

Other · developed by NEUROCRINE BIOSCIENCES

Phase 2 Most advanced trial

NBIX Developer

1 Registered trials

What is NBI-1117567?

NBI-1117567 is an investigational drug studied in Alzheimer's Disease.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: NEUROCRINE BIOSCIENCES (NBIX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07832383	Phase 2	Alzheimer's Disease	Not yet recruiting	NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer's Disease

More from NEUROCRINE BIOSCIENCES

Crinecerfont FDA approved Valbenazine FDA approved Chronocort Phase 3 DITEST Phase 1 Luvadaxistat Phase 2 NBI-1065845 Phase 3 NBI-1065890 Phase 2 NBI-1070770 Phase 2 NBI-1117568 Phase 3 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Sources

ClinicalTrials.gov NCT07832383

Updated Oct 3, 2026. Something wrong or missing? Report it on the NBIX page.

Follow NBIX, the company behind NBI-1117567

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z